A Comparative Study between 18F-FDG PET/CT and Conventional Imaging in the Evaluation of Progressive Disease and Recurrence in Ovarian Carcinoma.

PET/CT ovarian cancer treatment management

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
03 Jun 2021
Historique:
received: 05 04 2021
revised: 31 05 2021
accepted: 31 05 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

The aim of this study is to compare the efficiency of conventional imaging and 18F-FDG PET-CT in detecting progressive disease and recurrences over a period of one year (2018), in the case of ovarian cancer, and also to assess the importance of 18F-FDG PET/CT in changing the course of the treatment for these patients. This study included 29 patients diagnosed in various stages with ovarian carcinoma, most of them of epithelial origin. All patients were evaluated throughout their treatment using 18F-FDG PET/CT and various conventional techniques (computed tomography (CT), magnetic resonance imaging (MRI), abdominal and intravaginal ultrasound, chest X-ray). PET/CT was more useful and effective in our group of patients in detecting progressive disease compared with conventional imaging (37.93% vs. 17.24%) and also in establishing the recurrences (24.14% vs. 6.90%). Moreover, F18-FDG PET-CT led to a therapeutic change in 55.17% of the patients of our group, compared with only 17.24% after conventional imaging. This underlines the crucial aspect of the metabolic changes of tumors that should be assessed alongside the morphological ones, with PET-CT imaging remaining the only viable tool for achieving that at present. PET/CT with 18F-FDG represents one of the most important imaging techniques used in the diagnosis and management of ovarian carcinoma. Our results seem to fall in line with what other authors reported, indicating that 18F-FDG PET-CT is potentially gaining more ground in the management of ovarian carcinoma, by influencing therapeutic strategies and by being able to detect relapse and progression accurately.

Identifiants

pubmed: 34205173
pii: healthcare9060666
doi: 10.3390/healthcare9060666
pmc: PMC8229870
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Front Med (Lausanne). 2015 Jul 22;2:46
pubmed: 26258124
Obstet Gynecol. 2011 Mar;117(3):742-746
pubmed: 21343791
Semin Nucl Med. 2019 Nov;49(6):484-492
pubmed: 31630732
Radiology. 2002 May;223(2):495-9
pubmed: 11997559
Gynecol Oncol. 2008 Jan;108(1):160-5
pubmed: 17961640
Gynecol Oncol. 2016 Jan;140(1):29-35
pubmed: 26515076
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1079-1091
pubmed: 28180966
Ann Surg Oncol. 2012 Jun;19(6):1966-72
pubmed: 22124757
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):404-13
pubmed: 26381775
Clin Nucl Med. 2012 Aug;37(8):e184-8
pubmed: 22785525
J Turk Ger Gynecol Assoc. 2015 Aug 06;16(3):137-44
pubmed: 26401105
Gynecol Obstet Invest. 2017;82(1):47-53
pubmed: 27197526
Mol Imaging Biol. 2012 Feb;14(1):123-9
pubmed: 21240639
Medicine (Baltimore). 2018 Apr;97(17):e0098
pubmed: 29702969
Eur J Radiol. 2012 May;81(5):1002-6
pubmed: 21349672
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2009 Jul 9;361(2):170-7
pubmed: 19587342
Abdom Imaging. 2008 Jan-Feb;33(1):112-8
pubmed: 17404789
EJNMMI Res. 2016 Dec;6(1):42
pubmed: 27206785
Int J Gynecol Cancer. 2014 Sep;24(7):1190-4
pubmed: 24987918
Gynecol Oncol. 2010 Mar;116(3):389-94
pubmed: 19926121
Gynecol Oncol. 2006 Oct;103(1):271-6
pubmed: 16626793
Radiat Prot Dosimetry. 2015 Jul;165(1-4):194-8
pubmed: 25852181
Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):480-6
pubmed: 17089122
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Gynecol Oncol. 2013 Dec;131(3):689-93
pubmed: 24076062
Gynecol Oncol. 2017 Feb;144(2):405-413
pubmed: 27931752
Clinics (Sao Paulo). 2012;67(5):437-41
pubmed: 22666786
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1224-1232
pubmed: 29476227
JAMA. 2018 Feb 13;319(6):595-606
pubmed: 29450530
Radiology. 2016 Aug;280(2):576-84
pubmed: 26909647
J Pers Med. 2020 Jun 19;10(2):
pubmed: 32575591
Int J Gynaecol Obstet. 2008 Aug;102(2):124-7
pubmed: 18423470

Auteurs

George Rusu (G)

Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Patriciu Achimaș-Cadariu (P)

Ion Chiricuță Institute of Oncology, 400015 Cluj-Napoca, Romania.
Department of Surgical Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Andra Piciu (A)

Ion Chiricuță Institute of Oncology, 400015 Cluj-Napoca, Romania.
Department of Medical Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Simona Sorana Căinap (SS)

Department of Mother and Child, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Călin Căinap (C)

Ion Chiricuță Institute of Oncology, 400015 Cluj-Napoca, Romania.
Department of Medical Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Doina Piciu (D)

Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Ion Chiricuță Institute of Oncology, 400015 Cluj-Napoca, Romania.

Classifications MeSH